Editorial Dept. Voz de la Diaspora
British pharmaceutical company AstraZeneca expects that in the first half of 2021 begin the first shipments of a vaccine against COVID-19 that will be produced with Mexico and Argentina, in case clinical trials are successful, announced in a statement.
The company signed an agreement with the Carlos Slim Foundation to support production in both countries and distribution, no economic benefit from the potential COVID-19 vaccine, AZD1222, according to the statement.
The agreement will initially provide 150 million doses in the region, With the exception of Brazil, which will be covered by the agreement that AstraZeneca adopted with the Brazilian government last June.
The company said the alliance is an important milestone in its response to tackle the COVID-19 pandemic and support broad and equitable access to the vaccine., while working with Argentina and Mexico allows them to take advantage of their productive capacity to facilitate the early availability of the potential vaccine.
"It fills us with great satisfaction to be part of an alliance with partners in Latin America where our sole objective is to provide rapid access to the potential vaccine in Mexico and throughout the Latin American region", said the president and CEO of AstraZeneca, Mexico, Sylvia Varela.
In previous days the University of Oxford and AstraZeneca announced provisional results of a phase I clinical trial / II in the UK showing strong immune responses against SARS-CoV2 in all participants.
For its part, the Carlos Slim Foundation said that joining forces is vital to combat the pandemic in the region that has joined the search for a vaccine, hence its interest in supporting production in Mexico and Argentina in order to start supplying Latin America.
"In case its efficacy and safety is proven and it is approved by the health authorities, would contribute decisively to avoid further loss of life, and would allow the return to normality ", he added.